−0.0097 USD
6.92 M USD
140.24 K USD
240.02 M
About Endonovo Therapeutics, Inc.
Sector
Industry
CEO
Alan Brian Collier
Website
Headquarters
Woodland Hills
Founded
2008
FIGI
BBG00283C006
Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development, manufacture, and distribution of medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, and SofPulse Electroceutical Therapy. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ENDV is 0.0004 USD — it hasn't changed in the past 24 hours. Watch Endonovo Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Endonovo Therapeutics, Inc. stocks are traded under the ticker ENDV.
ENDV stock has fallen by −50.00% compared to the previous week, the month change is a −50.00% fall, over the last year Endonovo Therapeutics, Inc. has showed a −95.51% decrease.
ENDV reached its all-time high on Nov 7, 2014 with the price of 2,000.0000 USD, and its all-time low was 0.0004 USD and was reached on Dec 20, 2024. View more price dynamics on ENDV chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ENDV stock is 25.00% volatile and has beta coefficient of 0.04. Track Endonovo Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Endonovo Therapeutics, Inc. there?
Today Endonovo Therapeutics, Inc. has the market capitalization of 127.50 K, it has decreased by −46.67% over the last week.
Yes, you can track Endonovo Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ENDV net income for the last quarter is −697.13 K USD, while the quarter before that showed −721.29 K USD of net income which accounts for 3.35% change. Track more Endonovo Therapeutics, Inc. financial stats to get the full picture.
No, ENDV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Endonovo Therapeutics, Inc. EBITDA is −1.34 M USD, and current EBITDA margin is −1.62 K%. See more stats in Endonovo Therapeutics, Inc. financial statements.
Like other stocks, ENDV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Endonovo Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Endonovo Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Endonovo Therapeutics, Inc. stock shows the sell signal. See more of Endonovo Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.